Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 5, 2008, Pages 2172-2177

  Mochimaru, Hiroshi ^a,b,c   Usui, Tomohiko ^d   Yaguchi, Tomonori ^c   Nagahama, Yasuharu ^c   Hasegawa, Go ^c   Usui, Yoshihiko ^e   Shimmura, Shigeto ^b   Tsubota, Kazuo ^b   Amano, Shiro ^d   Kawakami, Yutaka ^c   Ishida, Susumu ^a,b,c  

^a Laboratory of Retinal Cell Biology   (Japan)

^b Department of Ophthalmology ^*  (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALI; BETA GALACTOSIDASE; CD4 ANTIBODY; CHROMIUM 51; DENDRITIC CELL VACCINE; EPITOPE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2; CYTOKINE; PEPTIDE FRAGMENT; SODIUM HYDROXIDE;

ANGIOGRAPHY; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; C57BL MOUSE; CAUSTIC BURN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHROMIUM 51 RELEASE; COCULTURE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; DOSE RESPONSE; DRUG TARGETING; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL; INTERFERON PRODUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CHEMICAL BURN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; EYE BURN; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; METABOLISM; VACCINATION;

ANIMALS; BURNS, CHEMICAL; CD8-POSITIVE T-LYMPHOCYTES; CORNEAL NEOVASCULARIZATION; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EYE BURNS; FLOW CYTOMETRY; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; SODIUM HYDROXIDE; VACCINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 44649199489     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1396     Document Type: Article

References (44)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
2. Usui T, Yamagami S, Yokoo S, Mimura T, Ono K, Amano S. Gene expression profile in corneal neovascularization identified by immunology-related macroarray. Mol Vis. 2004;10:832-836.
3. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351:2805-2816.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
6. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group: ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
7. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangio-genesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
8. Williams KA, Esterman AJ, Barlett C, Holland H, Hornsby NB, Coster DJ. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation. 2006;81:896 -901.
9. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/ pulse IL-2 therapy. J Clin Invest. 2001;108:51-62.
10. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia- induced retinal neovascularization. J Exp Med. 2003;198:483-489.
11. Ishida S, Yamashiro K, Usui T, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9:781-788.
12. Mochimaru H, Nagai N, Hasegawa G, et al. Suppression of choroi- dal neovascularization by dendritic cell vaccination targeting VEGFR2. Invest Ophthalmol Vis Sci. 2007;48:4795-4801.
13. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophalmol Scand. 2004;82:557-563.
14. Kim B, Suvas S, Sarangi PP, Lee S, Reisfeld RA, Rouse BT. Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects. J Immunol. 2006;177:4122- 4131.
15. Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002;195:1575-1584.
16. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8:1369-1375.
17. Wada S, Tsunoda T, Baba T, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005;65:4939-4946.
18. + T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother. 2006; 29:32-40.
19. Usui T, Yamagami S, Kishimoto S, Yokoo S, Nakayama T, Amano S. Roles of macrophage migration inhibitory factor in corneal neo- vascularization. Invest Ophthalmol Vis Sci. 2007;48:3545-3550.
20. Usui T, Ishida S, Yamashiro K, et al. VEGF164/165 as the pathological isoform: differential leukocyte and endothelial responses ia VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45: 368-374.
21. Yang JC, Perry-Lalley D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J mmunother. 2000;23:177-183.
22. Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997;12:117-123.
23. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
24. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003;63:4112-4118.
25. Udagawa M, Kudo-Saito C, Hasegawa G, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreat- ment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res. 2006;12:7465-7475.
26. Okamoto M, Furuichi S, Nishioka Y, et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004;64:5461-5470.
27. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune- mediated resistance to tumors. J Exp Med. 1997;186:1183-1187.
28. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180:347-52.
29. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
30. Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, Toda M. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J ancer. 2006; 118:942-949.
31. Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol. 2003;171:1534-1541.
32. Biancone L, Cantaluppi V, Boccellino M, et al. Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J Immunol. 1999;163:6201-6208.
33. Bussolino F, Ziche M, Wang JM, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. JClin Invest. 1991;87:986-995.
34. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 2002;16:225-227.
35. Koziel MJ, Dudley D, Afdhal N, et al. HLA class I-restricted cyto- toxic T lymphocytes specific for hepatitis C virus: identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest. 1995;96:2311-2321.
36. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146.
37. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8:275-283.
38. Ribatti D, Nico B, Pezzolo A, et al. Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma. Br J Cancer. 2006;94:1845-1852.
39. Qin Z, Schwartzkopff J, Pradera F, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003;63:4095-4100.
40. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. JClin Immunol. 1999;19:350-364.
41. Fujita S, Saika S, Kao WW, et al. Endogenous TNFa suppression of neovascularization in corneal stroma in mice. Invest Ophthalmol Vis Sci. 2007;48:3051-3055.
42. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol. 2001;70:317-325.
43. Smyth MJ, Sedgwick JD. Delayed kinetics of tumor necrosis factor- mediated bystander lysis by peptide-specific CD8+ cytotoxic T lymphocytes. Eur J Immunol. 1998;28:4162-4169.
44. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29:545-557.